Objective: The objective of the study is to investigate the relation between pretreatment depressive symptoms (DS) and the course of DS during the first year after cancer diagnosis, and overall survival among people with head and neck cancer (HNC).
| BACKGROUND
Clinical depression as well as depressive symptoms (DS) have been reported to increase mortality and reduce survival in different populations. [1] [2] [3] Among people with different types of cancer, those with a clinical diagnosis of minor or major depression have a 39% higher risk of dying during the follow-up period than people without depression. 1 People with increased levels of DS, as measured using validated patient-reported outcome measures, have a 25% higher risk of dying during the follow-up period. 1 People diagnosed with head and neck cancer (HNC) are prone to depression or DS. 4, 5 Previous studies on the association between clinical depression 6 or DS [7] [8] [9] [10] [11] [12] [13] and survival in people with HNC reported mixed results. Some studies reported no association, 7, 8 while others reported worse survival or higher mortality in people with depression or DS. 6, [9] [10] [11] [12] [13] Half of these studies were, however, limited by small number of events (eg, disease-related or overall deaths), 7, [9] [10] [11] [12] [13] hampering the ability to account for different covariates in the survival analyses.
In addition, most studies were limited to a single measurement of clinical depression or DS, 7, 8, [10] [11] [12] [13] mostly prior to treatment. 7, [10] [11] [12] [13] As previously reported, 14 pretreatment DS may result from the short-term response to cancer diagnosis and may not necessarily reflect a person's long-term course of DS and, therefore, may be a less important associated factor of survival than DS at follow-up.
A previous study reports that, in 40% of people with HNC, DS level indeed changed between the pretreatment and posttreatment measurement. 15 Four different courses of DS were identified: people without DS, people who developed DS (33%), people who recovered from DS (7%), and people with persistent DS (4%). A recent study comparing survival outcomes of people with lung cancer reported on 4 comparable courses of DS. 16 They found that people who developed or had persistent DS had an increased risk of earlier death, while people who recovered had the same risk as the reference group of people who never reported DS.
A recent large longitudinal study that measured depression more than once in people with HNC in relation to survival found that depression in the 2 years before HNC diagnosis as well as depression in the year after diagnosis was associated with worsened cancer-specific and overall survival. 6 In that study, however, no distinction was made between people who recovered from their depression during follow-up and those who did not. In addition, depression was defined as a registered clinical depression diagnosis based on Medicare claims data. The generalizability of these findings to people with DS or undiagnosed depression is unclear.
This study, therefore, aimed to investigate the relation between pretreatment DS as well as the course of DS during the first year after cancer diagnosis and overall survival among people with HNC.
| METHODS

| Design and study population
In this study, data from the Head and Neck 5000 prospective clinical cohort study was used (dataset version 2.1), 17, 18 including people with HNC from 76 centers in the United Kingdom. People with HNC were asked to participate if they had a new primary HNC diagnosis or were diagnosed with an unknown primary tumor likely to be HNC, and if they were ≥16 years. People were excluded if they did not have the capacity to provide informed consent or were too vulnerable for participation. In total, 5511 persons with HNC consented to participate from April 2011 to December 2014. For this particular study, we limited the population to people diagnosed with cancer of the oral cavity, oropharynx, hypopharynx, or larynx and those treated with curative intent. Besides, participants needed to have a baseline measurement of DS, and have complete socio-demographic, clinical, and lifestyle-related data.
All participants provided written informed consent. The study was approved by the National Research Ethics Committee (South West Frenchay Ethics Committee, reference 10/H0107/57, November 5, 2010) , and approved by the research and development departments for participating NHS Trusts.
| Measures
The English version of the Hospital Anxiety and Depression Scale (HADS) was used to assess psychological distress (HADS-total), level of DS (HADS-D), and level of anxiety symptoms (HADS-A) before the start of treatment, and at 4 and 12-month follow-up. 19, 20 A HADS-D > 7 was used as a cutoff for identifying persons with DS. 21 Internal consistency of the HADS-D in this study was α = .851.
Study-specific questions were used to measure pretreatment tobacco use and alcohol consumption. Tobacco use was categorized as current smoker, former smoker, or never smoked. 22 For alcohol consumption, people were categorized as nondrinkers, moderate drinkers (1-14 drinks per week), hazardous drinkers (14-35 drinks/ week for women and 14-50 drinks/week for men), or harmful drinkers (>35 drinks/week for women and >50 drinks/week for men). 22 In addition, age, gender, marital status, education level, annual household income, and deprivation status were measured. Deprivation status was measured using the Index of Multiple Deprivation (IMD) 2010. 23 24 At the start of the study, participants were flagged with the United Kingdom Health and Social Care Information Centre so that the study team was provided with information on overall mortality (mortality and mortality date).
| Clinical information
| Statistical analyses
All analyses were performed using the IBM Statistical Package for the Social Science (SPSS) version 23 (IBM Corp., Armonk, NY USA).
Chi-square tests and independent samples t-test analyses were used to analyze differences between groups.
To assess the association between pretreatment DS and overall survival, a series of Cox regression analyses were performed. At first, minimally adjusted analyses adjusted for age and gender were performed. Analyses were performed in the total population as well as in people with oral cavity, HPV-positive oropharyngeal, and HPV-negative oropharyngeal and laryngeal cancer separately. Survival time was defined as days from date of consent to censoring or date of death.
Besides these minimally adjusted analyses, we investigated whether potential associations remained after adjusting for socio-demographic and clinical factors. Also, Cox regression analyses adjusted for lifestyle-related factors were performed. Previous literature hypothesized that lifestyle may mediate the association between depression or DS and survival. 3, 25 However, other studies added lifestyle as a potential confounder to the model. 7, 8 Results can, therefore, be interpreted either as the direct effect after taking the potential mediating role of lifestyle into account or as the association that remains after adjusting for lifestyle as a potential confounder. Finally, post hoc analyses were performed by including each factor 1 by 1 to the minimally adjusted model, to investigate which factors had a strong influence on the association between DS and survival (defined as >10% change in hazard ratio (HR)). All categorical variables adhered to the proportional hazard assumption. Multicollinearity was not found. 
| RESULTS
The HADS-D score of the total study population (n = 2144) was on average 4.0 (standard deviation = 3.8, range 0-21). Eighteen percent (n = 384) had pretreatment DS ( This study showed that participants with pretreatment DS had a died during the follow-up period, which provided us with the opportunity to stratify our analyses and to adjust for a wide range of potential confounders. However, for the stratified analyses, additional analyses replicating our findings are warranted.
| Association between the course of depressive symptoms and overall survival
Besides worse survival in people with pretreatment DS, we also found that those with persistent/recurrent/late DS have higher risk of earlier death compared to the reference group of people who never experienced DS during the first year, while people who recovered from DS had the same risk. This is in line with results of a study among people with lung cancer. 16 These findings suggest that, as previously hypothesized, 14 Another pathway may be that untreated depression can cause suicide. 25 Although suicide is, compared to other diseases, relatively common among people with HNC, 28 in absolute terms, it is a rare event. Also, tumor-related and patient-related biomarkers of endocrine, immune, and autonomic (dys)function or other clinical variables may explain the association between depression and survival. 25 This might explain why we found a potential association between pretreatment DS and overall survival in people with HPV-negative oropharyngeal cancer and not in HPV-positive oropharyngeal cancer.
However, future research is warranted to replicate these findings and to explore the specific role of HPV status and other biomarkers. 
| Study limitations
| Clinical implications
People with pretreatment DS as well as persistent/recurrent/late DS are at increased risk of earlier death. Previous studies have hypothesized that lifestyle and suicide may explain (part of) this association.
Also, tumor-related or patient-related biomarkers are hypothesized to mediate this association. 
